Correspondence 0001213900-23-018102 from Jin Medical International Ltd. (ZJYL)
Jin Medical International Ltd.
Date: March 7, 2023 · CIK: 0001837821 · Accession: 0001213900-23-018102
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-259767
Referenced dates: March 2, 2023
Letter
Via Edgar Division of Corporation Finance Office of Industrial Applications and Services Amendment No. 11 to Registration Statement on Form F-1 Filed February 24, 2023 File No. 333-259767
Re: Jin Medical International Ltd.
Dear Ms. Park:
This letter is in response to the letter dated March 2, 2023, from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) addressed to Jin Medical International Ltd. (the “Company”, “we”, or “our”). For ease of reference, we have recited the Commission’s comment in this response. An amendment to the registration statement on Form F-1 (the “Amendment”) is being filed to accompany this letter.
Amendment No. 11 to Form F-1 filed February 24, 2023
Exhibits
1. We refer to your filing fee table filed as Exhibit 107 to your registration statement. Please revise your filing fee table to include separate entries for the Underwriters' Warrants and the ordinary shares underlying such warrants.
Response: The Company acknowledges the Staff’s comment and revised the filing fee table, which is being refiled as exhibit 107 to the Amendment.
We appreciate the assistance the Staff has provided with its comments. If you have any questions, please do not hesitate to call our counsel, Ying Li, Esq., of Hunter Taubman Fischer & Li LLC, at (212) 530-2206.
Very truly yours,
/s/ Erqi Wang
Show Raw Text
CORRESP
1
filename1.htm
March 7, 2023
Via Edgar
Ms. Jane Park
Division of Corporation Finance
Office of Industrial Applications and Services
U.S. Securities and Exchange Commission
Re:
Jin Medical International Ltd.
Amendment No. 11 to Registration Statement on Form F-1
Filed February 24, 2023
File No. 333-259767
Dear Ms. Park:
This letter is in response to the letter dated
March 2, 2023, from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”)
addressed to Jin Medical International Ltd. (the “Company”, “we”, or “our”). For ease of reference,
we have recited the Commission’s comment in this response. An amendment to the registration statement on Form F-1 (the “Amendment”)
is being filed to accompany this letter.
Amendment No. 11 to Form F-1 filed February
24, 2023
Exhibits
1. We
refer to your filing fee table filed as Exhibit 107 to your registration statement. Please revise your filing fee table to include separate
entries for the Underwriters' Warrants and the ordinary shares underlying such warrants.
Response: The Company acknowledges the
Staff’s comment and revised the filing fee table, which is being refiled as exhibit 107 to the Amendment.
We appreciate the assistance the Staff has provided
with its comments. If you have any questions, please do not hesitate to call our counsel, Ying Li, Esq., of Hunter Taubman Fischer &
Li LLC, at (212) 530-2206.
Very truly yours,
/s/ Erqi Wang
Name:
Erqi Wang
Title:
Chief Executive Officer
Cc: Ying Li, Esq.
Hunter Taubman Fischer & Li LLC